-
Mashup Score: 0Weekly Low-Dose Regimen of Decitabine and Venetoclax as Effective as Higher Dose | ASH Clinical News | American Society of Hematology - 1 month(s) ago
Lara C. Pullen, PhD, is a freelance medical writer in Chicago, Illinois. A metronomic, low-dose schedule of decitabine and venetoclax was deemed to be a safe and effective treatment for patients with myeloid malignancies. Patients with acute myeloid leukemia (AML) who received the combination experienced a median overall survival (OS) of 16.1 months, and patients with TP53 -mutated disease had an OS of 11.3 months. Mendel Goldfinger, MD, of Montefiore Medical Center in Bronx, New York, and colleagues
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Meletios-Thanos Dimopoulos, MD: Daratumumab Vs. Active Monitoring in High-Risk Smoldering Myeloma - 1 month(s) ago
ASH Clinical News Editor-in-Chief Aaron Gerds, MD, interviews Meletios-Thanos Dimopoulos, MD, at the 66th ASH Annual Meeting and Exposition to discuss his ab…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet-
Catch up on #ASH24 with ASH Clinical News! Below, @AaronGerds sat down with Dr. Meletios-Thanos Dimopoulos in San Diego to discuss the Aquila study and his findings on #daratumumab vs. active monitoring for high-risk #SmolderingMyeloma #SMM: https://t.co/5pINOvamTS
-
-
Mashup Score: 0More Work Needed to Overcome Racial, Ethnic AHCT Disparities in Multiple Myeloma | ASH Clinical News | American Society of Hematology - 2 month(s) ago
Katie Robinson is a medical writer based in New York. Autologous hematopoietic cell transplantation (AHCT) is a global standard of care for eligible patients with newly diagnosed multiple myeloma (MM), yet racial and ethnic disparities remain. According to findings published in Transplantation and Cellular Therapy, non-Hispanic Black patients had a longer time from diagnosis to AHCT and remained less likely to undergo AHCT compared with non-Hispanic white patients, though utilization rates have improved
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Despite improved #AHCT utilization rates among Black patients with #MultipleMyeloma over the last 10 years, such patients were found to have a longer time from diagnosis to AHCT and still remained less likely to undergo AHCT compared with white patients: https://t.co/N902UziaDP
-
-
Mashup Score: 1New Risk Classification Stratifies Outcomes in Older Intensively Treated Patients with AML | ASH Clinical News | American Society of Hematology - 2 month(s) ago
Lara C. Pullen, PhD, is a freelance medical writer in Chicago, Illinois. The new AML60+ classification provides prognostic information for intensively treated patients 60 years and older with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (HR-MDS). The classification, available in a free online tool, is easy to apply to routine clinical practice and provides crucial information on survival after allogeneic hematopoietic cell transplantation (alloHCT). Jurjen Versluis, MD, PhD, of
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Compared with previous classification systems for #AcuteMyeloidLeukemia, the new AML60+ classification provides improved prognostic information for older patients and could identify those who would benefit from intensive #chemotherapy and #alloHCT: https://t.co/Y2n1AWk2vc
-
-
Mashup Score: 2
ASH Clinical News Deputy Editor Bethany Samuelson Bannow, MD, interviews Anne de Vaan, MD, PhD candidate, at the 66th ASH Annual Meeting and Exposition to di…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet-
At #ASH24, @bsamuelson_md caught up with Dr. Anne de Vaan to discuss her research on #postpartum #hemorrhage in #hemophilia A and B carriers following enhanced prophylactic clotting factor suppletion. Check out their conversation below! https://t.co/YJiSuVvy3V
-
-
Mashup Score: 3David John Lewis, MD: Ibrutinib and Rituximab in Older Patients with Mantle Cell Lymphoma - 2 month(s) ago
ASH Clinical News Editor-in-Chief Aaron Gerds, MD, interviews David John Lewis, MD, at the 66th ASH Annual Meeting and Exposition to discuss his abstract on …
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet-
Catch on some of the groundbreaking research from #ASH24! Below, @AaronGerds sits down with Dr. David John Lewis to discuss his abstract on the use of #ibrutinib and #rituximab in in older patients with previously untreated #MantleCellLymphoma: https://t.co/73UB17nAYD
-
-
Mashup Score: 5BOVen Regimen NCCN-Approved Option for TP53-Mutated MCL | ASH Clinical News | American Society of Hematology - 2 month(s) ago
Leah Lawrence is a freelance health writer and editor based in Delaware. The three-drug regimen of zanubrutinib, obinutuzumab, and venetoclax—dubbed the BOVen regimen—is an effective option for patients with TP53 -mutated mantle cell lymphoma (MCL), according to results of a phase II study published in Blood. 1 This “chemo-free” regimen combining a BTK inhibitor, BCL2 inhibitor, and an anti-CD20 monoclonal antibody yielded a high overall response rate (ORR), high rates of complete response (CR), and a
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
The three-drug regimen of #zanubrutinib, #obinutuzumab, and #venetoclax was found to be an effective option for patients with TP53-mutated #MantleCellLymphoma, with an ORR of 96% and CR of 88%: https://t.co/Sbdp8HsDv7
-
-
Mashup Score: 0
Anna Azvolinsky, PhD, is a freelance medical and science journalist based in New York City. Many phase III cancer clinical trials exclude individuals with absolute neutrophil counts (ANCs) within the reference range for individuals with the Duffy null–associated ANC (DANC) phenotype. Many individuals with DANC are of African and Middle Eastern ancestry, and current clinical trials exclude some of these participants because of these predefined criteria. Individuals with DANC may also be receiving modified
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Recent findings show that many phase III #cancer clinical trials exclude individuals with absolute #neutrophil counts that are within the reference range for those with the Duffy null phenotype, with 76.5% of trials observed having such exclusion criteria: https://t.co/wBTZI6K9Hx
-
-
Mashup Score: 5
Lara C. Pullen, PhD, is a freelance medical writer in Chicago, Illinois. Historically, hematologists have feared Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) because of its poor prognosis. However, new research suggests that dual BCR::ABL1 kinase inhibition with dasatinib and asciminib is a safe treatment for patients with de novo Ph+ ALL. Marlise Luskin, MD, MSCE, of Dana-Farber Cancer Institute in Boston, and colleagues published their findings in Blood. “This is a rare
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
According to research published in @BloodJournal, combination treatment with #asciminib and #dasatinib was efficacious in Ph+ #AcuteLymphoblasticLeukemia (ALL), with all patients on study with de novo ALL achieving hematologic and cytogenetic remission: https://t.co/gT5vqdXwhk
-
-
Mashup Score: 0MRD-Guided Therapy Improves Quality of Life for Patients With CLL | ASH Clinical News | American Society of Hematology - 3 month(s) ago
Anna Azvolinsky is a science and health journalist based in New York City. Time-limited treatment with ibrutinib plus venetoclax in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) guided by measurable residual disease (MRD) significantly improves quality of life (QoL) for these patients, including mitigating fatigue. 1 The patients saw clinically relevant improvements after one year at the end of their combination therapy course, including a 9-point improvement in global
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
Time-limited, MRD-guided treatment with #ibrutinib plus #venetoclax in patients with R/R #ChronicLymphocyticLeukemia led to significant improvements in quality of life for these patients, including mitigating fatigue: https://t.co/8DFWWIW3Y5 #ASH24
-
A low-dose schedule of #decitabine and #venetoclax was found to be a safe and effective treatment for myeloid malignancies, resulting in a median OS of 16.1 months in patients with #AcuteMyeloidLeukemia and 11.3 months in those with TP53-mutated disease: https://t.co/VM2YH4KeBB